Paper Details

  1. Home
  2. Paper Details

Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome.

Author: BeckerW, BufeA, GehlharK, SchlaakM

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Allergen immunotherapy was evaluated in grass pollen-allergic children. No change in IgE levels was observed, but symptom scores were significantly reduced in the treated group. While allergen-specific IgG1, IgG2 and IgG4 levels increased, the ratio of IgG4 to IgG1 correlated most significantly with symptom scores.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Although allergen immunotherapy has been established as a treatment of type I allergy back in 1911, until now the underlying mechanisms have not been fully understood, nor are there any parameters which would allow one to monitor an ongoing treatment or to assess therapeutic success in t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2222.1999.00525.x

データ提供：米国国立医学図書館（NLM）

Monitoring Allergen Immunotherapy: The IgG4/IgG1 Ratio as a Potential Biomarker

The intricate world of allergies, characterized by exaggerated immune responses to harmless substances, presents a significant challenge for those affected. Allergen immunotherapy, a treatment approach that involves gradually introducing increasing doses of the allergen to desensitize the immune system, has emerged as a promising treatment option. This study investigates the potential of allergen-specific antibody levels, particularly the ratio of IgG4 to IgG1, as biomarkers to monitor the effectiveness of allergen immunotherapy.

A Promising Biomarker: IgG4/IgG1 Ratio Correlates with Clinical Outcome

The study revealed that while allergen immunotherapy did not significantly reduce IgE levels or skin prick test reactivity, it resulted in a significant increase in allergen-specific IgG1, IgG2, and IgG4 levels. Interestingly, the researchers found a significant correlation between the ratio of IgG4 to IgG1 and symptom scores, suggesting that this ratio may serve as a valuable biomarker to monitor treatment success. This finding offers a potential avenue for objectively assessing the effectiveness of allergen immunotherapy, providing valuable insights for clinicians and researchers.

Navigating the Sandstorms of Allergies: A Personalized Approach to Treatment

The study's findings highlight the importance of developing objective measures to monitor the progress of allergen immunotherapy. The IgG4/IgG1 ratio emerges as a promising biomarker for assessing treatment success, offering a valuable tool for personalized medicine. While further research is needed to validate this biomarker and fully understand its significance in the complex world of allergies, this study provides a valuable contribution to the ongoing quest for effective and personalized treatments for allergies.

Dr.Camel's Conclusion

This study suggests that the ratio of allergen-specific IgG4 to IgG1 may serve as a valuable biomarker for monitoring the success of allergen immunotherapy. This finding offers a potential avenue for objectively assessing treatment progress and tailoring treatment strategies to individual patients.

Date :
  1. Date Completed 1999-04-29
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

10202364

DOI: Digital Object Identifier

10.1046/j.1365-2222.1999.00525.x

Related Literature

Article Analysis
・Effective treatment of allergy
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.